Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tempest Therapeutics, Inc.MLND · Entity 7734 | Director | June 22, 2020 | June 23, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tempest Therapeutics, Inc.
Report date June 22, 2020 · Filed June 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2030-06-21 | Direct | 12,000 |
Reported balance
After 2020-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-22 · Grant · Acquired 12,000 · Balance 12,000 F1: One hundred percent (100%) of the shares subject to this option will vest on the earlier of (1) June 22, 2021 and (2) the date of the first Annual Meeting following the grant date, subject to the Reporting Person continuing to provide service to the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: One hundred percent (100%) of the shares subject to this option will vest on the earlier of (1) June 22, 2021 and (2) the date of the first Annual Meeting following the grant date, subject to the Reporting Person continuing to provide service to the Issuer through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2020 Filed Jun 23, 2020 07:07 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001544227-20-000034 · wf-form4_159291043384915.xml · derivative · entry 1 HOWE JOHN P MD · CIK 0001190348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-06-21 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option will vest on the earlier of (1) June 22, 2021 and (2) the date of the first Annual Meeting following the grant date, subject to the Reporting Person continuing to provide service to the Issuer through such date. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 16:38 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $11.59 | $0.00 |
DisclosureSEC source: 0001209191-19-038485 · doc4.xml · derivative · entry 1 HOWE JOHN P MD · CIK 0001190348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-06-19 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option will vest on June 20, 2020, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 16:48 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001209191-19-004241 · doc4.xml · derivative · entry 1 HOWE JOHN P MD · CIK 0001190348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2029-01-14 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option will vest on January 15, 2020, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| July 04, 2018 Filed Jul 6, 2018 18:33 UTC | Tempest Therapeutics, Inc. OVAS · Entity 7734 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001179110-18-009535 · edgar.xml · derivative · entry 1 HOWE JOHN P MD · CIK 0001190348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2028-07-04 F1 · derivative.exercise_date: The stock option will vest in twelve equal monthly installments at the end of each successive month following July 4, 2018. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 20:56 UTC | Tempest Therapeutics, Inc. OVAS · Entity 7734 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001179110-17-009554 · edgar.xml · derivative · entry 1 HOWE JOHN P MD · CIK 0001190348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: The stock option will vest in twelve equal monthly installments at the end of each successive month following June 21, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.